I hear you (and thanks for the kind words)... Howe
Post# of 148110
Leronlimab is safe, relatively inexpensive, easy to administer, but what's held us back so far (sadly) is the need to prove efficacy in a double-blinded clinical trial.
We're about to do precisely that. When that occurs and the data is stat sig, I sincerely don't believe any entity on Earth will be able to sweep Cytodyn under the rug any longer.
So far the FDA has been able to say "Show me the data." Once we show it, then it's game over... in the best way imaginable.